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Autoimmune thyroid diseases (AITD) and Type 1 diabetes (T1D) frequently occur in the same 
individual pointing to a strong shared genetic susceptibility. Indeed, the cooccurrence of T1D and 
AITD in the same individual is classified as a variant of the autoimmune polyglandular syndrome 
type 3 (designated APS3v). Our aim was to identify new genes and mechanisms causing the co-
occurrence of T1D+AITD (APS3v) in the same individual using a genome-wide approach. For our 
discovery set we analyzed 346 Caucasian APS3v patients and 727 gender and ethnicity matched 
healthy controls. Genotyping was performed using the Illumina Human660W-Quad.v1. The 
replication set included 185 APS3v patients and 340 controls. Association analyses were 
performed using the PLINK program, and pathway analyses were performed using the 
MAGENTA software. We identified multiple signals within the HLA region and conditioning 
studies suggested that a few of them contributed independently to the strong association of the 
HLA locus with APS3v. Outside the HLA region, variants in GPR103, a gene not suggested by 
previous studies of APS3v, T1D, or AITD, showed genome-wide significance (p<5×10−8). In 
addition, a locus on 1p13 containing the PTPN22 gene showed genome-wide significant 
associations. Pathway analysis demonstrated that cell cycle, B-cell development, CD40, and 
CTLA-4 signaling were the major pathways contributing to the pathogenesis of APS3v. These 
findings suggest that complex mechanisms involving T-cell and B-cell pathways are involved in 
the strong genetic association between AITD and T1D.
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1. INTRODUCTION
The most common autoimmune endocrine disorders are type 1 (autoimmune) diabetes 
(T1D) and autoimmune thyroid diseases (AITD). T1D and AITD are both characterized by 
T-cell infiltration and production of autoantibodies directed at the target organs (pancreatic 
islets and thyroid, respectively), resulting in their dysfunction or destruction [1]. 
Epidemiological data have shown that T1D and AITD frequently occur together in the same 
family and in the same individual, suggesting a strong shared genetic susceptibility [1]. In 
different studies, up to 44% of T1D patients were positive for thyroid antibodies (TAb) 
(thyroid peroxidase [TPO] and/or thyroglobulin [Tg] antibodies) [2;3]. Similarly, 2.3% of 
children with AITD have islet cell antibodies compared with 0% of controls [4]. Indeed, the 
co-occurrence of T1D and AITD in the same individual is classified as one of the variants of 
autoimmune polyglandular syndrome type 3 (APS3) [5] (since the phenotype of T1D+AITD 
in the same individual is a known as a variant of APS3 we refer to it as APS3v in this 
manuscript).
Family studies also support a strong shared genetic susceptibility to T1D and AITD. One of 
the largest family studies of T1D and AITD in the US [6;7], showed that among female 
diabetic probands Hashimoto’s thyroiditis (HT) was diagnosed in 54 – 75% of cases, and 
among female relatives, the frequency of HT was 22 – 44%. Two other studies, one from the 
UK [8] and one from Colombia [9] showed similar results. Thus, epidemiological data 
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support a significant shared genetic susceptibility to T1D and AITD. However, while much 
has been learned about the genetics of T1D and AITD individually, less is known about the 
joint genetic etiology of these two diseases.
In view of the strong evidence for shared susceptibility for T1D and AITD we have 
previously mapped joint susceptibility genes for T1D and AITD using linkage studies in a 
large cohort of multiplex families in which T1D and AITD clustered. We used both the 
candidate gene approach [10;11], and whole genome linkage approach [12]. A striking 
finding of these studies was that the phenotype of T1D+AITD in the same individual 
(APS3v) was a unique phenotype with a genetic predisposition distinct from that of T1D or 
AITD alone [10;12]. The most significant contribution to T1D+AITD (APS3v) genetic 
susceptibility came from a sequence variant in HLA-DR [13]. In addition to the HLA class 
II susceptibility contribution we mapped three non-MHC loci showing evidence for linkage 
- CTLA-4, PTPN22, and FOXP3 [10–12]. These genes as well as other genes, such as 
IL-2α/CD25 and TNFα have been reported by other groups studying APS3v [14]. The aim 
of the present study was to identify genes unique for APS3v using the robust genome wide 
association study (GWAS) approach in order to identify novel shared mechanisms and 
pathways for T1D and AITD.
2. PARTICIPANTS AND METHODS
2.1 Study participants
The project was approved by the Icahn School of Medicine Institutional Review Board. 
SEARCH for Diabetes in the Youth study participants ≥ 18 years old or a parent/guardian of 
participants < 18 years provided written informed consent for data collection including 
DNA. We performed a two-stage GWAS using a discovery set and an independent 
replication set.
Discovery set (Table 1A)—The discovery set included 346 non-Hispanic White (NHW) 
patients with T1D who were also confirmed to be positive for TPO antibodies. These 
patients represent a subset of the SEARCH for Diabetes in Youth study prevalent and 
incident cohorts (for a full description of the SEARCH cohort see [15]). T1D was based on 
physicians’ diagnosis of T1D and confirmed at the time of the SEARCH study visit based on 
a positive autoantibody titer for GAD65 or IA-2, consistent with the ADA criteria for type 
1A (autoimmune) diabetes [16]. Controls included 727 healthy Caucasians (NHW) that were 
obtained from the Illumina iControlDB database (http://genomeinformaticsalliance.org/
science/icontroldb.ilmn) [17]. Patients and controls were gender and ethnicity matched. The 
breakdown of the discovery set recruitment is detailed in Supplemental Table G.
Replication set (Table 1B)—The replication set included a separately enrolled dataset of 
185 Caucasian (NHW) patients with T1D+AITD (consisting of a T1D+AITD cohort 
previously described [13] with additional patients enrolled since 2010); 340 healthy 
Caucasians (NHW) were used as replication controls. The breakdown of the replication set 
recruitment is detailed in Supplemental Table G.
Tomer et al. Page 3













2.2 Genotyping and principal component analysis (PCA)
Genotyping of the cases and controls was performed at the Cincinnati Children’s Hospital 
Medical Center DNA core. DNA samples were genotyped using the Illumina Human660W-
Quad v1 BeadChips assays [18]. This chip provides 87% genomic coverage in Caucasians at 
r2 > 0.8. Quality control (QC) testing (including testing for Hardy-Weinberg equilibrium, 
identity by descent, missing rate < 5%, and minor allele frequency [MAF] > 0.01) was 
performed using PLINK (http://pngu.mgh.harvard.edu/purcell/plink/). 514,008 single 
nucleotide polymorphisms (SNPs) passed the QC testing and were used in the association 
analysis. To ensure that our cases and controls were appropriately matched for ethnicity, 
avoiding effects of population stratification, we performed Principal Component Analysis 
(PCA). For the PCA we used 100,000 representative SNPs from the GWAS panel and 
analyzed them using 2 PC’s [19]. Cases and controls were matched on their principal 
component scores. The program EIGENSOFT was used to perform the PCA [19].
2.3 Association analyses in the discovery set
After QC testing, association analysis was performed using PLINK for PCA matched 
samples (346 patients and 727 controls) via logistic regression while using the first 2 
principal components as covariates to adjust for the effect of population stratification on the 
results. SNPs with a p-value < 5×10−8 were considered to have genome-wide level of 
significance, while SNPs with a p-value ≤ 1×10−5 were considered showing suggestive 
evidence for association [18].
2.4 Replication set analysis
SNPs were selected for analysis in the replication set based on the following criteria: (1) To 
reduce the likelihood of false positive results there had to be at least 2 associated SNPs (p ≤ 
1×10−5) within the same gene in the discovery set for the gene to be analyzed in the 
replication set; (2) we did not analyze in the replication set SNPs within HLA class I & II 
genes (since these have already been shown to be strongly associated with APS3v [11;13]), 
as well as SNPs within multiple MHC genes that are in tight Linkage Disequilibrium (LD) 
with each other. Based on these criteria we selected for the replication set 116 SNPs 
showing suggestive evidence for association (p ≤ 1×10−5). To these we added 28 SNPs that 
showed borderline significance (p< 5×10−4), but were located within genes already selected 
for replication based on the above 2 criteria to improve coverage of these genes. The list of 
24 genes (containing 144 SNPs) with suggestive evidence for association that were tested in 
the replication set is shown in Supplemental Table A. These 144 SNPs were genotyped in 
the replication set using the Illumina custom-made Goldengate assays. PCA was not 
performed in the replication set since only 144 SNPs were genotyped in that set and they did 
not include ancestry informative markers. In order to test the effect the PCA might have had 
on the replication set we redid the association analysis on the 144 SNPs identified in the 
discovery set without adjusting the results by PCA. The analysis showed that for all the 
SNPs except one (rs4589926) the results with and without adjusting by PCA were 
comparable (Supplemental Table B). These results confirmed that the lack of adjustment for 
PCA in the replication set should have had minimal if any effect on the results.
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2.5 Meta-analysis combining the discovery and replication sets
The PLINK association output including odds ratio and standard error values were generated 
from the discovery and replication datasets, respectively. Meta-analysis was then performed 
on these two association outputs using PLINK to derive meta-p-values with Mantel-
Haenszel correction.
2.6 Linkage disequilibrium (LD) analysis
Linkage disequilibrium (LD) analysis was performed for the MHC and 1p13 loci since 
several genes in these loci were found to be associated with APS3v. For the LD analysis we 
used the Haploview program and analyzed the discovery set data [20].
2.7 Logistic regression analysis (Conditional haplotype-based testing)
MHC locus (6p)—To test whether the non-HLA genes within the MHC locus that showed 
genome-wide significant associations had independent effects or were associated due to 
strong LD with HLA class I and II genes (known to be associated with APS3v) we ran 
logistic regression models and performed a Likelihood Ratio- (LR) based omnibus 
association test on the discovery set. This analysis enabled us to test whether the overall 
haplotype variation of the SNPs within these genes influenced the presence of the APS3v 
phenotype. We then performed conditional LR-based tests in order to (1) test for an 
independent effect of each SNP (independent of the haplotypic effects formed by the 
remaining SNPs); and (2) test for any marginal omnibus significant association controlling 
for each SNP (i.e., we tested if for SNPs that had independent effects, the remaining SNPs in 
the haplotype jointly contributed association information beyond the tested SNP alone).
For this analysis we used 23 SNPs in the MHC region that showed genome wide 
significance. They included the 4 highest scoring SNPs within the HLA class II genes, 3 
highest scoring SNPs within the HLA class I genes, and 16 highest scoring SNPs within the 
non-HLA MHC genes that showed significant association (Supplemental Table C1). This 
analysis was performed using PLINK v1.07.
Chromosome 1p13 locus—Logistic regression analysis was also performed on the 4 
most associated SNPs within 4 genes in this locus, MAGI3, PHTF1, PTPN22, BCL2L15, in 
order to determine whether any of these genes had independent effects.
Chromosome 4q27 locus—3 SNPs within this locus showed significant associations 
with APS3v and we performed logistic regression analysis using allelic, as well as dominant 
and recessive models to determine which model is most likely contributing to the association 
with APS3v.
2.8 Pathway analysis
Pathway analysis was performed using the Meta-Analysis Gene-set Enrichment of variant 
Associations (MAGENTA) program (http://www.broadinstitute.org/mpg/magenta/). For the 
pathway analysis we used only the discovery dataset. The 1000 SNPs that had the lowest p-
values were used in this analysis. The probability that SNPs for a pathway/gene-set were 
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significantly enriched when compared to randomly selected SNP-sets was computed. A p-
value < 0.05 was considered significant.
3. RESULTS
3.1 Association analysis in the discovery set
Detailed characteristics of the discovery set are provided in Table 1. The discovery set 
included 346 Caucasian (NHW) APS3v patients; of them 216 (62%) were females and 130 
(38%) were males resulting in a female to male (F:M) ratio of 1.6:1. This ratio is 
significantly higher than the reported F:M ratio in T1D which is close to 1.0 [21], but is 
consistent with the female preponderance of AITD. The control discovery set consisted of 
727 North American Caucasians. There were 451 (62%) females and 276 (38%) males in the 
control group (F:M ratio 1.6:1). In order to control for population stratification we 
performed a PCA in the discovery set. PCA demonstrated that our APS3v patients and 
controls were ethnically matched North American Caucasians of European ancestry along 
the axes of statistically significant principal components. The lambda gc (genomics inflation 
factor) of the PCA was 1.016 demonstrating a very close ethnicity matching of patients and 
controls.
The quantile-quantile (QQ) plot, which illustrates results of the distribution of association 
analyses for all the tested SNPs, showed an excess of SNPs in several loci that were 
significantly associated with APS3v at the tail of the distribution (Supplemental Figure A, 
blue line). To examine the effects of HLA genes (known to be strongly associated with 
APS3v) on the QQ plot we re-analyzed the QQ plot after removal of SNPs within HLA class 
I and class II genes (Supplemental Figure A, red line). The QQ plot without HLA genes 
showed a substantial reduction in the number of SNPs that are significantly associated with 
APS3v, confirming the major role of HLA genes in the etiology of APS3v. The results of 
the association analysis using the Human660W-Quad v1 SNPs in APS3v patients compared 
to controls are summarized in the Manhattan plot shown in Figure 1. The strongest 
association was seen at the MHC (6p) locus with many SNPs in this locus showing genome 
wide significance (p < 5 × 10−8); however, other non-MHC loci also showed significant 
associations (Figure 1). 307 SNPs showed suggestive evidence of association (p ≤ 1 × 10−5) 
(Supplemental Tables D1 and D2).
3.2 Association analysis in the replication set
For the replication analysis we tested 144 selected SNPs. These SNPs were chosen because 
they were located within or near 24 genes-loci showing suggestive evidence of association 
(p ≤ 1×10−5) in at least 2 SNPs, excluding HLA class I and II genes. After QC, 11 SNPs 
were removed leaving a total of 133 that were analyzed. The replication analysis identified 
107 SNPs within 22 genes-loci that showed a nominal p-value of less than 0.05 
(Supplemental Table E). Of these, 20 genes-loci contained one or more SNPs that showed 
genome wide significance (p < 5×10−8) in the combined sets (Table 2) and one gene 
(MAGI3) had a SNP giving a combined p-value close to genome wide significance (p = 
4.18×10−7). Of these 21 replicated genes-loci, 16 are non-HLA genes located within the 
MHC locus on chromosome 6p (Figure 2), and 5 genes (MAGI3, PHTF1, PTPN22, 
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BCL2L15 and GPR103) are located outside the MHC locus. Interestingly 4 of the 5 non-
MHC genes (MAGI3, PHTF1, PTPN22, and BCL2L15) are located on chromosome 1p13.
3.3 Linkage disequilibrium (LD) analysis
LD analysis for the MHC region showed that the MHC gene-locus where the 16 replicated 
genes were located consisted of 4 LD blocks, suggesting that while some genes may show 
association with APS3v because of LD others may have independent contributions (Figure 
3A). LD analysis for the 1p13 locus showed tight LD between PHTF1 and PTPN22 and 
weaker LD between these two genes and BCL2L15, while MAGI3 did not show significant 
LD with the other 3 genes (Figure 3B), suggesting that more than one gene in this locus may 
have independent effects.
3.4 Logistic regression analysis (Conditional haplotype-based testing)
MHC locus (6p)—The overall variation of the haplotypes formed by the 23 SNPs located 
within associated MHC genes influenced the presence of the APS3v phenotype (omnibus 
association LR test p-value < 1×10−8). Intriguingly, even though the MHC region had 4 LD 
blocks only one gene, HSPA1L showed independent effect on disease risk after adjusting for 
the effect of the entire haplotype (Supplemental Table C1). SNP rs2227956, located within 
HSPA1L, showed the strongest independent effect (conditional LR test p-value=0.00227). 
Moreover, for rs2227956 (HSPA1L) we found that the other SNPs jointly contributed to the 
association with APS3v beyond the effect of rs2227956 alone (marginal omnibus 
association LR test p-value = 1.72×10−42, Supplemental Table C1).
Chromosome 1p13 locus—Logistic regression analysis was performed on the 4 most 
associated SNPs within 4 genes in this locus, MAGI3, PHTF1, PTPN22, BCL2L15, in order 
to determine whether any of these genes had independent effects. The analysis showed that 
only PTPN22 had independent effect on the susceptibility to APS3v (conditional LR test p-
value=0.008), suggesting that it is the causative gene and not the other 3 genes in this locus 
(Supplemental Table C2).
Chromosome 4q27 locus—3 SNPs in this locus showed significant association with 
APS3v by the logistic regression analysis. Analyses for allelic variation, as well as 
genotypic variation under dominant and recessive models all showed significant associations 
(Supplemental Table C3).
3.5 Pathway analysis
Pathway analysis was performed to provide insight into mechanisms underlying the etiology 
of APS3v. Several pathways were found to be significantly associated with APS3v 
(Supplemental Table F). The three most strongly associated pathways were cell cycle, B-cell 
development and CD40 signaling.
4. DISCUSSION
Organ-specific autoimmune diseases, such as T1D and AITD, share common underlying 
pathogenetic mechanisms. Indeed, genetic studies have demonstrated the existence of 
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common autoimmunity genes predisposing to several autoimmune diseases [1;22]. One of 
the strongest phenotypic associations between two different organ-specific autoimmune 
diseases is the association between T1D and AITD [1], suggesting a significant shared 
genetic susceptibility. In the current study we dissected the joint genetic susceptibility for 
T1D and AITD using a genome-wide approach, analyzing patients who developed both T1D 
and AITD (i.e. APS3v). Our data demonstrated that the majority of SNPs showing genome-
wide significant associations were located within or near the MHC locus. These findings 
confirm previous studies by us [13] and others [23;24] demonstrating the key role the MHC 
region plays in the etiology of APS3v.
The mechanism by which HLA class II proteins predispose to APS3v was shown by us to be 
through alteration of antigen presentation [13]. Antigen presentation is determined by the 
HLA class II pocket structure, which is genetically determined by its inherited sequence that 
has high population variability. Certain autoantigenic peptides that fit within the HLA class 
II pocket are more likely to be presented to T-cells that escaped tolerance thereby triggering 
disease [25].
We also identified SNPs in 16 additional non-HLA genes within the MHC region that were 
strongly associated with APS3v. In order to determine if they are associated with APS3v by 
virtue of LD with HLA class II or whether they confer independent effects we performed a 
conditional logistic regression analysis. Our logistic regression analysis suggested that at 
least one of these 16 non-HLA genes in the MHC region, HSPA1L, had an independent 
effect on the risk for disease (Supplemental Table C1). Moreover, LD analysis (Figure 3A) 
showed 4 LD blocks in the MHC region suggesting that other MHC genes may have 
independent effects that could not be detected in our dataset. Heat shock 70kDa protein 1-
like (HSPA1L) is a member of the heat shock proteins (HSPs) that are upregulated in cells 
in response to stressful stimuli, and have been previously shown to play a role in AITD and 
T1D [26]. Recently, the HSPA1L protein was identified in islets of enterovirus-associated 
fulminant type 1 diabetes suggesting a role in T1D [27].
In addition to the 16 MHC genes demonstrating significant associations with APS3v, we 
identified SNPs in 5 non-MHC genes that were associated with APS3v: BCL2L15 (B-cell 
lymphoma 2-like protein 5), MAGI3 (membrane associated guanylate kinase WW and PDZ 
domain containing 3), PHTF1 (putative homeodomain transcription factor 1), PTPN22 
(protein tyrosine phosphatase non-receptor type 22), and GPR103 (G protein-coupled 
receptor 103). Interestingly, 4 of the 5 non-MHC genes found to be associated with APS3v 
in our GWAS (MAGI3, PHTF1, PTPN22, BCL2L15) are located within a 350 Kb region on 
chromosome 1p13 suggesting that they are all in LD. LD analysis showed that only PHTF1 
and PTPN22 are in tight LD (Figure 3B). This suggested that more than one gene in this 
locus may have an independent effect on the etiology of APS3. However, logistic regression 
analysis demonstrated that only the PTPN22 gene had an independent effect on disease risk 
confirming earlier studies showing that PTPN22 is a major autoimmunity gene [1;28]. These 
results confirmed our previous studies, using linkage analysis that showed strong linkage of 
PTPN22 with APS3v [11;12]. The PTPN22 gene encodes the lymphoid tyrosine 
phosphatase (LYP) protein, a potent inhibitor of T-cell activation [29]. A non-synonymous 
SNP causing a tryptophan to arginine change at position 620 has been associated with 
Tomer et al. Page 8













several autoimmune diseases [1;28], but the substitution results in gain-of-function and 
increases suppression of T-cell receptor signaling. It is hypothesized that this substitution 
may allow escape of self-reactive T-cells from deletion by central tolerance [30].
The GPR103 gene is especially interesting since it is a novel gene-locus identified to be 
unique for the APS3v phenotype. The GPR103 gene (also designated as QRFPR gene) is a 
G-protein-coupled receptor that is expressed mostly in brain, but also in human pancreatic 
islets and it may have an effect on insulin secretion [31]. Moreover, the ligand for GPR103 
(P518) is expressed in thyroid cells [32]. Taken together these expression data suggest a role 
for GPR103 and/or its signaling pathway in APS3v. The GPR103 gene is located on 
chromosome 4q27 and it has not been previously reported to be associated with 
autoimmunity. However, a locus on chromosome 4q27 that is approximately 625 Kb 
downstream the GPR103 gene was previously reported to be associated with T1D [33], as 
well as with other autoimmune diseases including rheumatoid arthritis [34], Celiac disease 
[35], and ulcerative colitis [36]. Currently it is unclear whether this is the same locus as the 
one associated with APS3v, and further studies are needed to explore this possibility.
No previous studies tested the GPR103 locus on 4q27 for association with AITD, and 
therefore we tested the two GPR103 SNPs showing association with APS3v, for association 
with AITD in our AITD dataset (251 GD patients, 114 HT patients and 365 matched 
controls). The analysis showed that SNPs rs1513695 and rs7679475 were both associated 
with HT (p=0.04 and p=0.02, respectively) but not with GD. These data are consistent with 
the fact that most APS3v patients have HT and only a minority has GD [13].
Previous studies by us [12] and others [37] showed strong linkage and association of 
CTLA-4 with APS3v, while in the current study CTLA-4 markers did not reach genome 
wide significance. However, our pathway analysis did show significant association of the 
CTLA-4 signaling pathway with APS3v confirming earlier results. These data show the 
power of pathway analysis to identify important mechanisms underlying common diseases. 
Other pathways that were significantly associated with APS3v included cell cycle, B-cell 
development, CD40 signaling, death receptor signaling, IL12 and IL-2 signaling pathways. 
The association with CD40 signaling pathway is consistent with previous data showing that 
CD40 plays a role in the etiology of both AITD [38] and T1D [39]. The association with the 
IL-2 and IL-12 signaling pathways suggests that abnormalities in T-cell activation are also 
important to the etiology of APS3v.
The main limitation of our study is the small cohort size that may have limited our ability to 
identify common variants with weak effects. Even though our study had a relatively small 
sample size its main strength was the phenotype selection. All the patients in the discovery 
set developed both type 1 diabetes and TPO antibodies before age 20. The development of 
two autoimmune diseases in childhood supports a strong genetic contribution to the T1D
+AITD phenotype of our patients (since children have less time for environmental 
exposures), and therefore enabled us to identify the strongest genetic effects in our cohort.
Several GWAS studies have been performed in T1D (reviewed in [40]) identifying over 30 
genes-loci. By far the strongest association is with the MHC locus. Similarly, in our study 
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the HLA class II genes showed the strongest association (Supplemental Table D1), and 16 
out of the 21 genes we identified were located within the MHC region. Therefore, for both 
phenotypes, T1D alone and T1D+AITD (APS3v), the MHC region is the most important 
susceptibility locus. Among non-MHC genes the PTPN22 overlapped between T1D and 
APS3v, suggesting that some T1D susceptibility genes have a major contribution to the 
APS3v phenotype, as well. Several genes are specific to the APS3v phenotype. These 
include the CTLA-4 gene that has been previously shown to be unique for APS3v [11;37], 
and the GPR103 gene identified in the current study. These data support the notion that 
APS3v is a unique phenotype with specific genetic susceptibility.
In summary, this is the first GWAS study performed in patients that developed both T1D
+AITD in childhood. Our data support a major role for MHC genes with contributions from 
non-MHC genes. Identifying the mechanisms by which these genes predispose to disease 
will hopefully facilitate the development of novel mechanism-based therapeutic strategies.
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• Autoimmune thyroiditis (AITD) and Type 1 diabetes (T1D) are genetically 
associated.
• We mapped multiple loci predisposing to T1D+AITD using a genome wide 
approach.
• Sixteen genes were non-HLA genes located in the MHC locus.
• We identified GPR103 as a novel susceptibility gene for T1D+AITD.
• Major pathways predisposing to T1D+AITD included CD40 and CTLA-4 
signaling.
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Manhattan plot showing the results of the association analysis in the Discovery set. The X-
axis shows the chromosomal location of the analyzed SNPs and the Y-axis shows the – 
log(p-value). As expected the strongest association was seen on chromosome 6 at the MHC 
(HLA) locus with many SNPs in this locus showing genome wide significance (p < 5×10−8); 
however, other non-MHC loci also showed significant associations.
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Schematic diagram of the MHC region showing non-HLA genes within the MHC locus 
found to be associated with T1D+AITD (APS3v). Of 21 replicated genes 16 were located 
within the MHC locus on chromosome 6p but are not HLA genes. Shown are HLA-A, HLA-
C, and HLA-DQB1 (gray boxes), as well as 9 of the 16 genes within the MHC region that 
were replicated. Gene names are indicated below the line representing chromosome 6p and 
their chromosomal location in bp is indicated above the line.
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(A) Linkage disequilibrium (LD) analysis of SNPs within 16 MHC genes that were 
replicated. LD analysis showed that the MHC region, where the replicated genes are located, 
consisted of 4 LD blocks. These results suggested that while some genes that are located 
within the same LD block (e.g. HCP5 and MICA) may show association with APS3v 
because of LD, others that are outside these blocks may have independent contributions. (B) 
LD analysis of the 1p13 locus. The PHTF1 and PTPN22 genes show tight LD with a D’ of 
0.99 while the BCL2L15 gene was in weaker LD with PTPN22 (D’=0.85) and PHTF1 
(D’=0.93). In contrast, MAGI3 was not in LD with the other 3 genes at the locus showing 
D’<0.80 with all 3 genes.
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Table 1
A: Discovery Set: Non-Hispanic White Participants with Type 1 Diabetes (N=346) from the SEARCH for Diabetes in Youth Study, 








    Age at diagnosis (y) [Mean (SD)] 8.5 (4.2) 8.5 (3.9) 8.4 (4.7) 0.7 8
    Age at study visit (y) [Mean (SD)] 13.9 (4.0) 13.8 (4.1) 14.1 (4.0) 0.66
    Disease duration (y) [Mean (SD)] 5.0 (4.5) 4.9 (4.5) 5.1 (4.4) 0.43
    TPO-Ab (IU/L) [Mean (SD)] 15.9 (10.0) 16.0 (10.1) 15.6 (9.3) 0.75
Additional diagnosis [n (%)]
    Hypothyroidism 55/346 (16%) 39/216 (18%) 16/129 (12%) 0.18
    Hyperthyroidism 24/345 (7%) 17/216 (8%) 7/129 (5%) 0.51
    Vitiligo 6/343 (1.7%) 3/215 (1.4%) 3/128 (2.3%) 0.68
    Addison disease 1/345 (0.3%) 1/216 (0.5%) 0 1
    Celiac disease 0 0 0 -
Family History of DM [n (%)]
    Mother 21/344 (6%) 9/215 (4%) 12/129 (9%) 0.065
    Father 20/340 (6%) 12/214 (6%) 8/126 (6%) 1.00
    Maternal grandfather 52/324 (16%) 33/198 (17%) 18/128 (14%) 0.64
    Maternal grandmother 58/335 (17%) 34/208 (16%) 24/127 (19%) 0.40
    Paternal grandfather 55/318 (17%) 33/199 (17%) 22/119 (18%) 0.76
    Paternal grandmother 53/318 (16%) 29/207 (14%) 24/121 (20%) 0.21
Age at the time of Diagnosis DM 
(years, Mean (SD)]
    Mother 24.7 (11.8) 25.3 (11.2) 24.4 (12.5) 0.99
    Father 31.7 (15.9) 31.5 (15.3) 32.0 (18.1) 0.95
    Maternal grandfather 55.1 (15.8) 57.5 (13.5) 51.0 (18.8) 0.55
    Maternal grandmother 54.6 (14.3) 52.5 (16.5) 58.9 (6.0) 0.78
    Paternal grandfather 56.2 (16.5) 57.9 (16.0) 54.3 (17.5) 0.44
    Paternal grandmother 51.0 (21.6) 52.4 (23.0) 49.4 (20.5) 0.52







Age of diagnosis (y) [Mean (SD)] 19.7 (14.3) 20.5 (15.4) 17.9 (11.5)
Age of inclusion (y) [Mean (SD)] 43.5 (14.5) 46.1 (14.5) 37.8 (12.6)
Additional diagnosis [n (%)]
    Hashimotos’ Thyroiditis 146/185 (79%) 108/128 (84%) 38/57 (67%)
    Graves’ Disease 39/185 (21%) 20/128 (16%) 19/57 (33%)
n, Number, y, Years, SD, Standard Deviation. TPO-Ab, Thyroid Peroxydase Antibodies, DM, Diabetes Mellitus (any type)
*
p-Values are for comparing Females vs. Males
n, Number, y, Years, SD, Standard Deviation.
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